New Delhi, Oct. 24 -- Dr Reddy's Laboratories beat street estimates in the September quarter, with a revenue of Rs.8,805 crore and profit after tax of Rs.1,437 crore, buoyed by growth in branded markets and its nicotine replacement therapy (NRT) portfolio.

A Bloomberg poll of 26 brokerages had pegged the drugmaker's consolidated revenue at Rs.8,706.2 crore and its profit after tax at Rs.1,397.5 crore.

The Hyderabad-based firm's revenue grew nearly 10% year-on-year (y-o-y) and 3% sequentially, while its profit after tax was up 14% y-o-y, despite the drag of price erosion in its largest market, the US.

Dr Reddy's revenue in North America declined 13% y-o-y and 5% sequentially to Rs.3,241 crore, primarily due higher price erosion in some ...